Skip to Main Content

Paper Details

The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.
Endocr Relat Cancer
22
2021
AR, AR-low, BRD4, CRPC, CRPC tumors, CRPCs, EZH2, LSD1, SOX2, amphicrine, androgen, androgen receptor, androgens, castration-resistant prostate cancer, cell, double, nBAF complex, prostate cancer, prostate cancers, tumor, tumors
Author NameAffiliation
Joshi J AlumkalRogel Cancer Center, University of Michigan ann arbor
Ilsa ColemanFred Hutchinson Cancer Research Center
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington School of Medicine
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington School of Medicine
Colm MorrisseyUniversity of Washington School of Medicine
  • 1 - 9

Datasets

Release 1.2